Regulatory effects of Dangua Humai Oral Liquid on gut microbiota and mucosal barrier in mice with glucolipid metabolism disorder.
10.19540/j.cnki.cjcmm.20250421.401
- Author:
Zhuang HAN
1
;
Lin-Xi JIN
1
;
Zhi-Ta WANG
1
;
Liu-Qing YANG
1
;
Liang LI
1
;
Yi RUAN
1
;
Qi-Wei CHEN
1
;
Shu-Hong YAO
1
;
Xian-Pei HENG
1
Author Information
1. People's Hospital Affiliated to Fujian University of Traditional Chinese Medicine Fuzhou 350004, China.
- Publication Type:Journal Article
- Keywords:
Dangua Humai Oral Liquid;
glucolipid metabolism disorder;
gut microbiota;
lipid metabolism;
mucosal barrier
- MeSH:
Animals;
Gastrointestinal Microbiome/drug effects*;
Mice;
Intestinal Mucosa/microbiology*;
Male;
Drugs, Chinese Herbal/administration & dosage*;
Mice, Inbred C57BL;
Humans;
Glycolipids/metabolism*;
Lipid Metabolism/drug effects*;
Administration, Oral;
Disease Models, Animal
- From:
China Journal of Chinese Materia Medica
2025;50(15):4315-4324
- CountryChina
- Language:Chinese
-
Abstract:
The gut microbiota regulates intestinal nutrient absorption, participates in modulating host glucolipid metabolism, and contributes to ameliorating glucolipid metabolism disorder. Dysbiosis of the gut microbiota can compromise the integrity of the intestinal mucosal barrier, induce inflammatory responses, and exacerbate insulin resistance and abnormal lipid metabolism in the host. Dangua Humai Oral Liquid, a hospital-developed formulation for regulating glucolipid metabolism, has been granted a national invention patent and demonstrates significant clinical efficacy. This study aimed to investigate the effects of Dangua Humai Oral Liquid on gut microbiota and the intestinal mucosal barrier in a mouse model with glucolipid metabolism disorder. A glucolipid metabolism disorder model was established by feeding mice a high-glucose and high-fat diet. The mice were divided into a normal group, a model group, and a treatment group, with eight mice in each group. The treatment group received a daily gavage of Dangua Humai Oral Liquid(20 g·kg~(-1)), while the normal group and model group were given an equivalent volume of sterile water. After 15 weeks of intervention, glucolipid metabolism, intestinal mucosal barrier function, and inflammatory responses were evaluated. Metagenomics and untargeted metabolomics were employed to analyze changes in gut microbiota and associated metabolic pathways. Significant differences were observed between the indicators of the normal group and the model group. Compared with the model group, the treatment group exhibited marked improvements in glucolipid metabolism disorder, alleviated pathological damage in the liver and small intestine tissue, elevated expression of recombinant claudin 1(CLDN1), occluding(OCLN), and zonula occludens 1(ZO-1) in the small intestine tissue, and reduced serum levels of inflammatory factors lipopolysaccharides(LPS), lipopolysaccharide-binding protein(LBP), interleukin-6(IL-6), and tumor necrosis factor-α(TNF-α). At the phylum level, the relative abundance of Bacteroidota decreased, while that of Firmicutes increased. Lipid-related metabolic pathways were significantly altered. In conclusion, based on the successful establishment of the mouse model of glucolipid metabolism disorder, this study confirmed that Dangua Humai Oral Liquid effectively modulates gut microbiota and mucosal barrier function, reduces serum inflammatory factor levels, and regulates lipid-related metabolic pathways, thereby ameliorating glucolipid metabolism disorder.
